Neurocrine Biosciences (NBIX) Precio de Acción, Cotización, Noticias e Historial | Benzinga

Neurocrine Biosciences Inc (NBIX) Precio de Acción, Cotización, Noticias e Historial

NBIXNASDAQ

Trade with Public

Trade with Public

$141.84

3.492.52%

Últ. Act.: Sep 30, 4:48 PM

$141.00

2.651.92%

Panorámica generalNoticias Previsión de beneficios Eventos Precios objetivo Finanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

© 2026 Benzinga | All Rights Reserved

Estadísticas Clave

Apertura

$138.33

Cierre

$141.84

Volumen / Prom.

1.85M / 1.24M

Rango diario

$137.63 - $142.91

Rango de 52 semanas

122.14 - 186.12

Capitalización bursátil

$14.18B

Ratio PER

20.23

Rentabilidad por dividendo

-

Exchange

NASDAQ

RSI

35

Interés en corto

6.43%

Días para cubrir

5.37

Noticias Recientes de Neurocrine Biosciences, Inc.

Jim Cramer Says Buy Uber, Calls Rockwell Automation 'One Ugly Chart' but a 'Great Long-Term Situation'

Jim Cramer recommended buying Uber, Tanger, Rockwell Automation, Amcor, and Neurocrine Biosciences. Uber and Zipline announced a partnership for autonomous delivery. Tanger and Amcor both reported better-than-expected earnings. Rockwell Automation and Neurocrine Biosciences had mixed reactions from analysts. Uber and Amcor shares fell, while Tanger, Rockwell Automation, and Neurocrine Biosciences shares all had varying degrees of movement.

Avi Kapoor

What's Going On With Neurocrine Biosciences Stock On Wednesday?

Reports of serious adverse events and deaths linked to Neurocrine's VYKAT XR for Prader-Willi syndrome prompt caution.

Vandana Singh

Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys

Tom Lee's GRNJ added First Solar, Zoom and eight other stocks in its latest rebalance as assets under management climbed to $476 million.

Chandrima Sanyal

Arista Networks To Rally Around 43%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on top names. See all analyst rating changes, including upgrades and downgrades, on our analyst ratings page.

Avi Kapoor

Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market

Neurocrine (NBIX) to acquire Soleno Therapeutics (SLNO) for $2.9B to expand its rare disease portfolio. Get the deal details here.

Vandana Singh

Finanzas

Trimestral

Anual

Nombre

Ingresos Variación
Bruto Variación
EBITDA Variación
EBIT Variación
Beneficios Variación

Flujos de Caja

Flujo de Caja Operativo (TTM)

898.10M

Flujo de Caja de Inversión (TTM)

-891.20M

Flujo de Caja de Financiación (TTM)

60.20M

Flujo de Caja Libre (TTM)

870.40M

Gasto de Capital (TTM)

-27.70M

Cambio Neto en Efectivo (TTM)

67.10M

Tendencia de los analistas

2

jun

12

2

jul

3

1

ago

3

1

sept

Compra

Mantener

Venta

Venta fuerte

Calificación de analistas

3.9

Compra

Compra fuerte

Compra

Mantener

Venta

Venta fuerte

Métricas de Valoración

Valor Empresarial

$14.08B

Relación P/E (TTM)

20.23

Relación P/E (FWD)

13.79

Relación PEG (TTM)

0.28

Relación P/S (TTM)

4.25

Relación P/B (TTM)

3.81

Rendimiento de Ganancias % (TTM)

4.94%

Rendimiento de Ganancias % (FWD)

7.25%

EV / EBITDA (TTM)

15.28

Precio / EBITDA (TTM)

15.54

Precio / Flujo de Caja Libre (TTM)

16.46

Valor Contable / Acción

$36.34

Deuda Empresarial

Deuda Total

-

Deuda a Largo Plazo

-

Emisión de Deuda a Largo Plazo (TTM)

-

Reembolso de Deuda a Largo Plazo (TTM)

-$600.00M

Efectivo Total

$332.40M

Deuda a Capital

0.11

Emisión de Deuda (TTM)

$0

Reembolso de Deuda (TTM)

-$600.00M